company background image
PNT

POINT Biopharma Global NasdaqCM:PNT Stock Report

Last Price

US$7.22

Market Cap

US$762.8m

7D

1.3%

1Y

14.6%

Updated

27 Jan, 2023

Data

Company Financials +

POINT Biopharma Global Inc.

NasdaqCM:PNT Stock Report

Mkt Cap: US$762.8m

PNT Stock Overview

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer.

PNT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

POINT Biopharma Global Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for POINT Biopharma Global
Historical stock prices
Current Share PriceUS$7.22
52 Week HighUS$10.98
52 Week LowUS$5.23
Beta0.059
1 Month Change6.96%
3 Month Change-26.18%
1 Year Change14.60%
3 Year Changen/a
5 Year Changen/a
Change since IPO-39.93%

Recent News & Updates

Recent updates

A Look At The Fair Value Of POINT Biopharma Global Inc. (NASDAQ:PNT)

Oct 18
A Look At The Fair Value Of POINT Biopharma Global Inc. (NASDAQ:PNT)

Shareholder Returns

PNTUS BiotechsUS Market
7D1.3%0.7%2.3%
1Y14.6%7.1%-9.7%

Return vs Industry: PNT exceeded the US Biotechs industry which returned 10.5% over the past year.

Return vs Market: PNT exceeded the US Market which returned -8.5% over the past year.

Price Volatility

Is PNT's price volatile compared to industry and market?
PNT volatility
PNT Average Weekly Movement12.8%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: PNT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: PNT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201972Joe McCannhttps://www.pointbiopharma.com

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies.

POINT Biopharma Global Inc. Fundamentals Summary

How do POINT Biopharma Global's earnings and revenue compare to its market cap?
PNT fundamental statistics
Market CapUS$762.76m
Earnings (TTM)-US$79.17m
Revenue (TTM)n/a

0.0x

P/S Ratio

-9.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PNT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$79.17m
Earnings-US$79.17m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.75
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PNT perform over the long term?

See historical performance and comparison